Sight Sciences (NASDAQ:SGHT) Stock Rating Reaffirmed as Overweight by Piper Sandler

Sight Sciences (NASDAQ:SGHT)‘s stock had its “overweight” rating reissued by equities research analysts at Piper Sandler in a report issued on Thursday, Benzinga reports. They presently have a $12.00 price objective on the stock, up from their prior price objective of $9.00. Piper Sandler‘s price objective indicates a potential upside of 19.05% from the company’s previous close.

SGHT has been the topic of several other research reports. Wall Street Zen upgraded Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. UBS Group raised their price target on shares of Sight Sciences from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 6th. HC Wainwright started coverage on shares of Sight Sciences in a research report on Thursday, October 15th. They issued a “buy” rating and a $14.00 price objective on the stock. Finally, Citigroup lifted their price objective on shares of Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday, October 5th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $9.62.

Sight Sciences Stock Up 3.3%

Shares of NASDAQ:SGHT traded up $0.32 on Thursday, reaching $10.08. The company had a trading volume of 576,378 shares, compared to its average volume of 290,147. The firm has a market capitalization of $555.31 million, a PE ratio of -19.38 and a beta of 2.44. The company has a current ratio of 4.95, a quick ratio of 4.67 and a debt-to-equity ratio of 0.58. Sight Sciences has a 52-week low of $3.38 and a 52-week high of $10.31. The firm’s 50 day simple moving average is $8.72 and its 200-day simple moving average is $6.09.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). Sight Sciences had a negative return on equity of 43.39% and a negative net margin of 35.69%. The firm had revenue of $24.92 million during the quarter, compared to analysts’ expectations of $23.55 million. As a group, analysts expect that Sight Sciences will post -0.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Paul Badawi sold 29,653 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total transaction of $268,359.65. Following the transaction, the chief executive officer directly owned 6,092,819 shares in the company, valued at $55,140,011.95. The trade was a 0.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James Rodberg sold 7,208 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $8.85, for a total value of $63,790.80. Following the transaction, the chief financial officer directly owned 216,829 shares in the company, valued at $1,918,936.65. This represents a 3.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 47,646 shares of company stock worth $429,157. 30.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sight Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of Sight Sciences during the second quarter worth about $16,710,000. Dimensional Fund Advisors LP raised its position in shares of Sight Sciences by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company’s stock valued at $1,288,000 after purchasing an additional 40,346 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Sight Sciences by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 293,358 shares of the company’s stock valued at $1,106,000 after purchasing an additional 17,458 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Sight Sciences in the 2nd quarter worth approximately $908,000. Finally, Bank of America Corp DE acquired a new stake in Sight Sciences in the 2nd quarter worth approximately $520,000. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Key Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: HC Wainwright raised its FY2027 EPS forecast to a loss of $0.20 from a projected loss of $0.24, suggesting it expects losses to narrow more than previously anticipated. It also forecasts quarterly losses improving from $0.09 in Q1 2027 to $0.02 in Q3. Sight Sciences analyst estimates
• Negative Sentiment: The firm cut its FY2026 EPS estimate to a loss of $0.45 from $0.40 and its Q4 2026 estimate to a loss of $0.09 from $0.08. These revisions point to somewhat weaker near-term earnings expectations. Sight Sciences analyst estimates

About Sight Sciences

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.